INDO BORAX & CHEMICAL LTD

Indo Borax & Chemicals Limited reported a 31% increase in operating revenues and a 59% rise in net profits for Q1 FY27, with EBITDA and PAT margins at 28.1% and 22.3% respectively. The company highlighted its 50% market share in Boric Acid and recent acquisition of 64.26% of Kronox Lab Sciences, which is expected to expand its global presence and product portfolio. Management emphasized operational efficiencies, capacity optimization, and strategic acquisitions as key drivers of growth. The company also outlined plans for Capex of Rs. 50 crores over two to three years, focusing on Boron Oxide and Boric Acid expansions. The acquisition of Kronox includes a Rs. 110 crore Capex plan, funded through internal accruals and existing cash reserves. The company noted that while Q2 FY27 is expected to be weaker due to monsoon season, full-year revenue guidance remains at Rs. 250-260 crores with a 20% EBITDA margin. Strategic initiatives include cross-selling opportunities, expanding into higher-margin I.P. grade Boric Acid, and exploring import substitution under Atmanirbhar Bharat. The leadership team emphasized long-term value creation and integration of Kronox's global distribution network.

The document emphasizes strong financial performance, strategic acquisitions, and growth plans, with management highlighting confidence in future prospects and operational improvements.